Tumour microenvironment and focal therapy for prostate cancer

Basit Öğe Kaydı
dc.authorid0000-0002-6308-1763
dc.contributor.authorBorges, Rafael Castilho
dc.contributor.authorTourinho-Barbosa, Rafael Rocha
dc.contributor.authorde la Rosette, Jean J. M. C. H.
dc.date.accessioned2022-05-27T07:55:58Z
dc.date.available2022-05-27T07:55:58Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı
dc.description.abstractPurpose of review Although most studies focus on the tumour component of prostate cancer (PCa), increasing attention is being paid to the prostatic tumour microenvironment (TME) and its role in diagnosis, prognosis, and therapy development. Herein, we review the prognostic capability of tumour and nontumour derived biomarkers, the immunomodulatory effects of focal therapy (FT) on TME, and its potential as part of a multidisciplinary approach to PCa treatment. Recent Findings Tumour cells have always been the natural candidates to explore new biomarkers, but recent evidence highlights the prognostic contribution of TME cell markers. TME plays a critical role in PCa progression and tumours may escape from the immune system by establishing a microenvironment that suppresses effective antitumour immunity. It has been demonstrated that FT has an immunomodulatory effect and may elicit an immune response that can either favour or inhibit tumorigenesis. TME shows to be an additional target to enhance oncological control. Summary A better understanding of TME has the potential to reliably elucidate PCa heterogeneity and assign a prognostic profile in accordance with prostate tumour foci. The joint contribution of biomarkers derived from both tumour and TME compartments may improve patient selection for FT by accurately stratifying disease aggressivity according to the characteristics of tumour foci. Preclinical studies have suggested that FT may act as a TME modulator, highlighting its promising role in multimodal therapeutic management.
dc.identifier.citationBorges, R. C., Tourinho-Barbosa, R. R. ve de la Rosette, J. J. M. C. H.(2022). Tumour microenvironment and focal therapy for prostate cancer. Current Opinion in Urology, 32(3), 248-253. https://doi.org/10.1097/MOU.0000000000000987
dc.identifier.doi10.1097/MOU.0000000000000987
dc.identifier.endpage253
dc.identifier.issn0963-0643
dc.identifier.issn1473-6586
dc.identifier.issue3
dc.identifier.pmid35552306
dc.identifier.scopus2-s2.0-85130023000
dc.identifier.scopusqualityQ2
dc.identifier.startpage248
dc.identifier.urihttps://doi.org/10.1097/MOU.0000000000000987
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9468
dc.identifier.volume32
dc.identifier.wos000793972800007en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorde la Rosette, Jean
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofCurrent Opinion in Urologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectFocal Therapy
dc.subjectImmune System
dc.subjectProstate Cancer
dc.subjectTumour Immunology
dc.subjectTumour Microenvironment
dc.titleTumour microenvironment and focal therapy for prostate cancer
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
de la Rosette-Jean-2022.pdf
Boyut:
700.67 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu